ECLI:NL:RBAMS:2025:8836

Rechtbank Amsterdam

Datum uitspraak
28 oktober 2025
Publicatiedatum
18 november 2025
Zaaknummer
C/13/773734
Instantie
Rechtbank Amsterdam
Type
Uitspraak
Rechtsgebied
Civiel recht
Uitkomst
Toewijzend
Procedures
  • NCC
Rechters
Vindplaatsen
  • Rechtspraak.nl
Aangehaalde wetgeving Pro
Art. 1.3.4 NCC procesreglementArt. 24 lid 2 Brussel 1bis-verordeningArt. 25 Brussel 1bis-verordeningArt. 26 Brussel 1bis-verordeningArt. 32a Rv
AI samenvatting door LexboostAutomatisch gegenereerd

Toewijzing van benoeming niet-uitvoerende bestuurders op grond van aandeelhoudersovereenkomst en Nederlands vennootschapsrecht

In deze zaak staan Batavia Biopharma BV (BBP) en CJ Cheiljedang Corporation (CJ) tegenover elkaar over de vraag of BBP het recht heeft om niet-uitvoerende bestuurders te benoemen bij Batavia Biosciences BV (de Onderneming) op grond van de aandeelhoudersovereenkomst, de statuten en het Nederlandse vennootschapsrecht.

De voorzieningenrechter van de NCC beoordeelde eerst de bevoegdheid van de rechtbank en de toepasselijkheid van Nederlands recht. De rechtbank stelde vast dat zij bevoegd is op grond van de Brussel 1bis-verordening en het NCC-procesreglement, mede omdat CJ buiten Nederland is gevestigd en de statutaire zetel van de Onderneming in Nederland ligt. Ook werd bevestigd dat de partijautonomieregel van toepassing is en dat het geschil binnen de bevoegdheid van de NCC valt.

Tijdens de zitting verzochten partijen de voorzieningenrechter om overleg met de Ondernemingskamer over mogelijke onafhankelijke kandidaten voor niet-uitvoerende bestuurders. Vervolgens bereikten partijen een schikking over de benoeming van twee voorgedragen personen. De voorzieningenrechter wees de benoeming toe, verklaarde het vonnis uitvoerbaar bij voorraad en bepaalde dat partijen elk hun eigen kosten dragen.

De uitspraak bevestigt dat benoeming van bestuurders een passende voorziening is in kort geding en benadrukt het belang van partijautonomie binnen de kaders van het Nederlandse vennootschapsrecht en internationale bevoegdheidsregels.

Uitkomst: De rechtbank wijst de vordering toe en benoemt de voorgedragen personen als niet-uitvoerende bestuurders bij Batavia Biosciences BV.

Uitspraak

judgment

AMSTERDAM DISTRICT COURT

Netherlands Commercial Court
NCC Court in Summary Proceedings
Case number: C/13/773734
Judgment

28 October 2025

Claimant:
BATAVIA BIOPHARMA B.V.,
Alphen aan den Rijn (the Netherlands),
represented by R.Q. Potter, M.G. Dudink and C.R.B. Jonker, lawyers,
Defendant:
BATAVIA BIOSCIENCES B.V.,
Leiden (the Netherlands),
represented by I. Koudstaal and T.A.A.M. van Kemenade, lawyers,
Defendant:
CJ CHEILJEDANG CORPORATION
Seoul (Republic of Korea),
represented by A.W.P. Marsman, lawyer
The parties are referred to as BBP, the Company and CJ.
The term ‘lawyer’ has the meaning as defined in Article 3.1.1 NCC Rules of Civil Procedure (NCCR).

1.Procedural history

1.1.
On 8 August 2025, the Court granted BBP permission to serve a summons with notice to appear at a CSP [1] hearing on 30 September 2025. The writ of summons was subsequently served on 15 August 2025.
1.2.
On 26 September 2025, CJ submitted its statement of defence. The Company submitted a letter, waiving its right to submit a statement of defence.
1.3.
The hearing was held on 30 September 2025. The parties submitted speaking notes in advance, and at the hearing they presented their arguments to the Court and discussed various issues. During the hearing the parties also explored avenues to settle the case. They requested the Court to confer with the Enterprise Chamber of the Amsterdam Court of Appeal on potential independent candidates who may be willing to serve as non-executive directors at the Company.
1.4.
On 10 October 2025, the Court presented a list of three candidates to the parties.
1.5.
On 21 October 2025, BBP notified the Court that it had reached an agreement with CJ on two of the suggested candidates and requested the Court to appoint them as Founders Directors and therefore as non-executive directors at the Company.
1.6.
On 24 October 2025, in response to the Court’s directions dated 23 October 2025:
  • BBP confirmed that under the agreement it withdrew all claims previously submitted and entered an amended claim for the Court to issue a judgment (a) making the appointment as per the message dated 21 October 2025, (b) declaring the judgment enforceable notwithstanding appeal and (c) ordering each party to bear its own costs,
  • CJ confirmed the agreement and supported the request for judgment as delineated above, in accordance with the amended claim,
  • the Company confirmed that it does not oppose the settlement agreement and the requested appointment by the Court.

2.The dispute

BBP and CJ are the shareholders of the Company. The core issue is whether BBP is entitled under the Shareholders’ Agreement (signed by the parties on 9 December 2021 (the SHA)), the Company’s Articles of Association and Dutch corporate law to effectively appoint persons of its choosing as non-executive directors at the Company.

3.BBP’s amended claims and the defendants’ position

3.1.
In its amended claim, BBP seeks a judgment – enforceable notwithstanding appeal – for the appointment of [director 1] and [director 2] as Founders Directors and – as a result – as non-executive directors at the Company. Each party is to bear its own costs, in the amended claim.
3.2.
CJ supports the amended claim and the Company does not oppose it.

4.Discussion

4.1.
Before turning to the matter at hand, the Court must first, on its own initiative, determine whether the requirements for the Court’s jurisdiction and NCC authority have been met (Article 1.3.4 NCC Rules of Procedure) and whether Dutch law governs the dispute.
Jurisdiction and NCC authority
4.2.
The requirements are dealt with in this paragraph: (a) jurisdiction; (b) internationality; and (c) NCC authority and the party autonomy rule.
( a) Jurisdiction.
The Court is satisfied that the Amsterdam District Court has jurisdiction to deal with this case pursuant to Article 25 (and 26) of the Brussels 1bis Regulation, as the parties agreed that the Amsterdam District Court has jurisdiction for disputes resulting from the SHA (Clause 18.12 of the SHA). The exclusive jurisdiction rule in Article 24(2) Brussels 1bis Regulation does not apply, as the dispute focuses on the performance of a shareholders’ agreement, not on other issues such as the nullity of a board decision. [2] Also, the relief requested (the appointment of a director) is not within the exclusive jurisdiction of the Enterprise Chamber. [3]
( b) Internationality.
The internationality requirement (Article 32a Dutch Code of Civil Procedure, DCCP) is met, as CJ is domiciled outside of the Netherlands (in the Republic of Korea).
( c) NCC authority and the party autonomy rule.
In the SHA, the parties designated the NCC as the appropriate chamber to deal with all disputes arising out of or in connection with the SHA (Clause 18.12 of the SHA). The dispute here concerns performance of the SHA, which is a legal relationship within the parties’ autonomy. That generally is enough to accept NCC authority, and since BBP seeks an interim measure here, the CSP is the appropriate chamber to deal with this dispute, unless a specific rule applies.
The ‘party autonomy rule’ in Article 32a DCCP is a specific rule, which the Court must consider. [4] This rule requires that issues presented to the NCC be within the parties’ autonomy. The Court’s holding is that the party autonomy rule is limited in scope: it removes issues from NCC authority only where (a) the public interest may be impacted or (b) there are issues directly affecting third parties (which is potentially or actually inconsistent with public policy). [5] Only in such circumstances are the parties bereft of their autonomy. Accordingly, the mere fact that mandatory provisions of corporate law may apply here, in one way or another, does not render this dispute out of the NCC’s scope. No issues regarding the public interest or directly affecting third parties are presented here and the party autonomy rule is satisfied.
Applicable law
4.3.
Turning to the issue of governing law, the Court is persuaded that Dutch law applies. The Company’s statutory seat is in the Netherlands and Dutch law therefore provides the rules on the internal organisation of the Company (Article 10:118 in connection with Article 10:119(b) of the Dutch Civil Code). Any issues regarding the shareholders’ contractual obligations are – under Clause 18.11 of the SHA – governed by and construed in accordance with the laws of the Netherlands.
The merits of the case
4.4.
The Court is satisfied that BBP and CJ have reached an arrangement that they understand and are comfortable with, along the lines of the amended claim. The Company does not oppose the amended claim. The Court is persuaded that the appointment of directors is an appropriate form of relief in summary proceedings here. On this basis, it is obvious that relief in summary proceedings, along the lines of the amended claim, is appropriate and that the requirements for an order in summary proceedings have been met. The amended claim is allowed. Each party must bear its own costs.

5.Order

THE COURT
5.1.
appoints [director 1] and [director 2] as Founders Directors and as non-executive directors at the Company,
5.2.
declares that this judgment is enforceable notwithstanding appeal,
5.3.
orders that each party must bear its own costs.
Done by L.S. Frakes, Judge, assisted by W.A. Visser, Clerk of the Court.
Issued in public on 28 October 2025.
APPROVED FOR DISTRIBUTION IN eNCC

Voetnoten

1.Court in Summary Proceedings
2.Even if the opposite were held, the Dutch courts would still have jurisdiction as the Company is domiciled in the Netherlands
3.See Amsterdam Court of Appeal (Enterprise Chamber) 7 March 2023, para. 5.6, publication number ECLI:NL:GHAMS:2023:583
4.The specific text expressing this rule in Article 32a DCCP is: “